Fig. 3.

Schema representing interactions between menopausal status (microenvironment levels of oestrogen), tumour associated biomarkers and treatment with zoledronate. Use of adjuvant zoledronate in combination with premenopausal levels of reproductive hormones and unfavourable biomarker expression such as amplification of the transcription factor MAF is associated with adverse disease outcomes. Conversely, use of adjuvant zoledronate in combination with postmenopausal levels of reproductive hormones and favourable tumour biomarkers such as normal levels of MAF or/and expression of CAPG/GIPC1 is associated with improved disease outcomes [23], [25].